evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/geneAliases/4,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract
19465,GENE_SUMMARY,,"EPAS1, a hypoxia-related transcription factor, is mutated or amplified in a small subset of human cancers.",,2017-04-04,,2034,EPAS1,endothelial PAS domain protein 1,False,ENST00000263734,NM_001430.4,MOP2,PASD2,ECYT4,HIF2A,bHLHe73,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
19466,GENE_BACKGROUND,,"EPAS1 encodes a transcription factor, also known as hypoxia-inducible factor 2-alpha (HIF2α), that binds the hypoxia response element (HRE) present in the promoter of genes related to conditions of oxygen deficiency, such as the vascular endothelial growth factor (VEGF) (PMID: 11301389). Under normoxic conditions, EPAS1/HIF2α is hydroxylated on specific prolyl sites and recognized by tumor suppressor VHL, leading to ubiquitination and degradation in the proteasome (PMID: 18498744). Under hypoxic conditions, EPAS1/HIF2α escapes degradation and activates genes involved in the hypoxia response, including angiogenesis, glycolysis, apoptosis, proliferation, and growth (PMID: 22089927, 14645546). EPAS1 has shown angiogenic and oncogenic properties in vivo in neuroendocrine tumor models (PMID: 23533246, 26432405). EPAS1 is mutated or amplified in a small subset of cancers. In contrast, in pheochromocytomas and paragangliomas, rare neuroendocrine tumors in which conditions of pseudo-hypoxia occur, several EPAS1 gain-of-function mutations, affecting key prolyl hydroxylation sites, have been reported (PMID: 22931260, 24741025, 23418310). Although HIF inhibitors have been proposed for cancer treatment, the complex and often contradictory roles of these factors suggests careful evaluation (PMID: 22169972).",,2017-04-04,,2034,EPAS1,endothelial PAS domain protein 1,False,ENST00000263734,NM_001430.4,MOP2,PASD2,ECYT4,HIF2A,bHLHe73,False,18498744,Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.,Molecular cell,2018-05-23T20:08:00,30,4,393-402,Kaelin WG Jr et al,doi: 10.1016/j.molcel.2008.04.009,,2018-05-23T04:02:00,,14645546,Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation.,Molecular and cellular biology,2017-12-01T20:03:00,23,24,9361-74,Hu CJ et al,,,0001-12-01,,26432405,PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma.,Cancer research,2018-11-01T20:15:00,75,21,4617-28,Mohlin S et al,doi: 10.1158/0008-5472.CAN-15-0708,,0001-11-01,,23533246,In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.,Endocrine-related cancer,2018-06-01T20:13:00,20,3,349-59,Toledo RA et al,doi: 10.1530/ERC-13-0101,,0001-06-01,,22931260,Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia.,The New England journal of medicine,2018-09-06T20:12:00,367,10,922-30,Zhuang Z et al,doi: 10.1056/NEJMoa1205119,,0001-09-06,,22169972,HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression.,Nature reviews. Cancer,2017-12-15T20:11:00,12,True,2001-09-22,Keith B et al,doi: 10.1038/nrc3183,,0001-12-15,,11301389,Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma.,Cancer,2018-04-15T20:01:00,91,8,1429-36,Xia G et al,,,0001-04-15,,22089927,Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases.,Cold Spring Harbor symposia on quantitative biology,2011,76,,335-45,Kaelin WG Jr,doi: 10.1101/sqb.2011.76.010975,,Kaelin WG Jr. Cold Spring Harbor symposia on quantitative biology. 2011;76()335-45.,,24741025,Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.,Endocrine-related cancer,2018-06-01T20:14:00,21,3,495-504,Welander J et al,doi: 10.1530/ERC-13-0384,,2018-06-01T05:04:00,,23418310,Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.,Human molecular genetics,2018-06-01T20:13:00,22,11,2169-76,Comino-Méndez I et al,doi: 10.1093/hmg/ddt069,,0001-06-01,
